ClinicalTrials.gg
CompletedNCT00159653Updated Feb 21, 2021

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

A Phase 3 interventional study of Xalacom and Xalatan in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 55 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing latanoprost in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Latanoprost · Glaucoma, Open-Angle.

Enrollment
4th of 39
500 · median 117
Started
2005
with 3 others
Phase 3
12 of 40
none open now
Registered
4th of 40
by date
Lead sponsor
9 of 40
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 40 studies testing latanoprost in Glaucoma, Open-Angle, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2005, is one of 12 in phase 3, and was the 4th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 40 studies testing latanoprost in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About latanoprost

Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing latanoprost in Glaucoma, Open-Angle as a file.
02

Study summary

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.
  • History of (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
500 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The mean IOP measurements obtained in the study eye at each time point

07

Study locations

55 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85032, United States
  • Pfizer Investigational Site
    Poway, California 92064, United States
  • Pfizer Investigational Site
    Redding, California 96002-2122, United States
  • Pfizer Investigational Site
    Redding, California 96002, United States
  • Pfizer Investigational Site
    Danbury, Connecticut 06810-4004, United States
  • Pfizer Investigational Site
    Cape Coral, Florida 33904, United States
  • Pfizer Investigational Site
    Lakeland, Florida 33805-2440, United States
  • Pfizer Investigational Site
    Ormond Beach, Florida 32174, United States
  • Pfizer Investigational Site
    Tampa, Florida 33603, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30322, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30349, United States
  • Pfizer Investigational Site
    Morrow, Georgia 30260, United States
  • Pfizer Investigational Site
    Homewood, Illinois 60430, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66213, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40207, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71104, United States
  • Pfizer Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Pfizer Investigational Site
    Saint Joseph, Michigan 49085, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68506, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68198-5540, United States
  • Pfizer Investigational Site
    Newark, New Jersey 07103-2499, United States
  • Pfizer Investigational Site
    Bethpage, New York 11714-5701, United States
  • Pfizer Investigational Site
    New York, New York 10029-6574, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28210, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28262, United States
  • Pfizer Investigational Site
    High Point, North Carolina 27262, United States
  • Pfizer Investigational Site
    Matthews, North Carolina 28105, United States
  • Pfizer Investigational Site
    Wilmington, North Carolina 28403, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Pfizer Investigational Site
    Cranberry Township, Pennsylvania 16066, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15238-3103, United States
  • Pfizer Investigational Site
    Mount Pleasant, South Carolina 29464-3060, United States
  • Pfizer Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    North Charleston, South Carolina 29406, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Amarillo, Texas 79106, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Calgary, Alberta T2T 5R6, Canada
  • Pfizer Investigational Site
    Nanaimo, British Columbia V9R 5B6, Canada
  • Pfizer Investigational Site
    Moncton, New Brunswick E1C 2N7, Canada
  • Pfizer Investigational Site
    Saint John, New Brunswick E2L 1G3, Canada
  • Pfizer Investigational Site
    Saint John, New Brunswick E2L 4W3, Canada
  • Pfizer Investigational Site
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Pfizer Investigational Site
    Barrie, Ontario L4M 4S5, Canada
  • Pfizer Investigational Site
    Markham, Ontario L6B 1A1, Canada
  • Pfizer Investigational Site
    Mississauga, Ontario L5A 4E4, Canada
  • Pfizer Investigational Site
    Oakville, Ontario L6H 3P1, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M6H 2H1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1V 1G5, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 0M7, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7K 3H3, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jul 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00159653
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jul 2005
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xalacom · Latanoprost · Timolol

Start the discussion